<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63337">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02281357</url>
  </required_header>
  <id_info>
    <org_study_id>D2210C00013</org_study_id>
    <nct_id>NCT02281357</nct_id>
  </id_info>
  <brief_title>Phase 3 Study to Evaluate the Efficacy &amp; Safety of Tralokinumab in Adults &amp; Adolescents With OCS Dependent Asthma</brief_title>
  <acronym>TROPOS</acronym>
  <official_title>A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Reducing Oral Corticosteroid Use in Adults and Adolescents With Oral Corticosteroid Dependent Asthma (TROPOS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multicentre, Randomized, Double-blind, Parallel Group, Placebo Controlled, Phase 3 Study
      to Evaluate the Efficacy and Safety of Tralokinumab in Reducing Oral Corticosteroid
      dependent Asthma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, parallel group, placebo-controlled study designed to
      evaluate the efficacy and safety of a fixed 300 mg dose of tralokinumab administered
      subcutaneously every 2 weeks in adult and adolescent subjects with oral corticosteroid
      dependent asthma. Approximately120 subjects will be randomized globally. Subjects will
      receive tralokinumab or placebo, administered via subcutaneous injection at the study site,
      over a 40-week treatment period.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change from baseline in the daily, average, OCS dose at week 40 post randomization while not losing asthma control.</measure>
    <time_frame>Week 40</time_frame>
    <description>To evaluate the effect of tralokinumab compared to placebo in reducing the prescribed, OCS maintenance dose in adult and adolescent subjects with asthma requiring chronic treatment with maintenance OCS in addition to ICS/LABA.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference between tralokinumab vs. placebo in the proportion of subjects with final daily average OCS dose ≤5 mg at Week 40 post randomization.</measure>
    <time_frame>Week 40</time_frame>
    <description>To evaluate the effect of tralokinumab compared to placebo on the proportion of subjects with the prescribed, OCS maintenance dose ≤5 mg in adults and adolescent subjects with asthma requiring chronic treatment with maintenance OCS in addition to ICS/LABA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference between tralokinumab vs. placebo in the proportion of subjects with ≥50% reduction in average daily OCS dose at Week 40 post randomization.</measure>
    <time_frame>Week 40</time_frame>
    <description>To evaluate the effect of tralokinumab compared to placebo on the proportion of subjects with at least 50% reduction in their prescribed, OCS maintenance dose in adult and adolescent subjects with asthma requiring chronic treatment with maintenance OCS in addition to ICS/LABA.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety and tolerability of tralokinumab assessed by the reporting of adverse events/serious adverse events and assessments for physical examination, electrocardiogram, laboratory values and vital signs.</measure>
    <time_frame>Week 0 to Week 40</time_frame>
    <description>To evaluate the safety and tolerability of tralokinumab.</description>
  </other_outcome>
  <other_outcome>
    <measure>Overall OCS exposure measured by the area under the dose curve.</measure>
    <time_frame>Week 0 to Week 40</time_frame>
    <description>To evaluate the effect of tralokinumab vs. placebo in overall OCS exposure.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline daily average OCS dose classified as: 100% reduction (no OCS); &gt;=90% to &lt;100% reduction; &gt;=75% to &lt;90% reduction; &gt;=50% to &lt;75% reduction; &gt;0% to &lt;50% reduction; no change or increased average OCS dose</measure>
    <time_frame>Week 0 to Week 40</time_frame>
    <description>To evaluate the effect of tralokinumab vs. placebo in the proportion of subjects that have decreased their daily average prescribed OCS dose.</description>
  </other_outcome>
  <other_outcome>
    <measure>Asthma exacerbation rate reduction.</measure>
    <time_frame>Week 0 to Week 40</time_frame>
    <description>To evaluate the effect of tralokinumab compared with placebo on asthma exacerbations.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent change from baseline in pre-bronchodilator FEV1, Forced Vital Capacity (FVC) and Forced Expiratory Flow (FEF) 25-75%.</measure>
    <time_frame>Week 12 and Week 40</time_frame>
    <description>To evaluate the effect of tralokinumab compared with placebo on lung function.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in baseline in bi-weekly mean daily asthma symptom score (combined daytime and night-time score as captured in the Asthma Daily Diary).</measure>
    <time_frame>Week 12 and Week 40</time_frame>
    <description>To evaluate the effect of tralokinumab compared with placebo on asthma symptoms and other asthma control metrics.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in rescue medication use.</measure>
    <time_frame>Week 12 and Week 40</time_frame>
    <description>To evaluate the effect of tralokinumab compared with placebo on asthma symptoms and other asthma control metrics.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in home peak expiratory flow (morning and evening).</measure>
    <time_frame>Week 12 and Week 40</time_frame>
    <description>To evaluate the effect of tralokinumab compared with placebo on asthma symptoms and other asthma control metrics.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in the number of night-time awakening due to asthma.</measure>
    <time_frame>Week 12 and Week 40</time_frame>
    <description>To evaluate the effect of tralokinumab compared with placebo on asthma symptoms and other asthma control metrics.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in Asthma Control Questionnaire-6 (ACQ-6).</measure>
    <time_frame>Week 12 and Week 40</time_frame>
    <description>To evaluate the effect of tralokinumab compared with placebo on asthma symptoms and other asthma control metrics.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in Standardised Asthma Quality of Life Questionnaire for 12 Years and older (AQLQ(S)+12).</measure>
    <time_frame>Week 12 and Week 40</time_frame>
    <description>To evaluate the effect of tralokinumab compared with placebo with regards to asthma specific health-related quality of life.</description>
  </other_outcome>
  <other_outcome>
    <measure>European Quality of Life -5 Dimension -5 Level Daily Living Questionnaire (EQ-5D-5L)</measure>
    <time_frame>Week 12 and Week 40</time_frame>
    <description>To evaluate the effect of tralokinumab compared with placebo with regards to health related quality of life.</description>
  </other_outcome>
  <other_outcome>
    <measure>Asthma specific resource utilization and Work Productivity and Activity Impairment Questionnaire plus Classroom Impairment Questions (WPAI+CIQ) scores.</measure>
    <time_frame>Week 12 and Week 40</time_frame>
    <description>To evaluate the effect of tralokinumab compared with placebo with regards to Healthcare Resource Utilization (HRU) and productivity loss due to asthma.</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic parameters (Ctrough at steady state)</measure>
    <time_frame>Week 0 to Week 40</time_frame>
    <description>To evaluate the pharmacokinetics of tralokinumab.</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence rate of positive anti-drug antibodies (ADA) including the characterizationof their neutralizing potential.</measure>
    <time_frame>Week 0 to Week 40</time_frame>
    <description>To evaluate the immunogenicity of tralokinumab.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">218</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Tralokinumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tralokinumab subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo subcutaneous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tralokinumab</intervention_name>
    <description>Tralokinumab dose</description>
    <arm_group_label>Tralokinumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1) Age 12-75 2) Documented physician-diagnosed asthma. 3) Documented treatment with ICS at
        a total daily dose corresponding to ≥500µg fluticasone propionate dry powder formulation
        and a LABA. 4) Subjects must have received OCS for the treatment of asthma for 6 months
        prior to Visit 1 and on a stable OCS dose between ≥7.5 to ≤30mg daily or daily equivalent
        for at least one month prior to enrolment (Visit 1) . 5) Pre-BD FEV1 value &lt;80% (&lt;90% for
        patients 12-17 yrs of age) of their PNV. 6) Post-BD reversibility of ≥12% in FEV1.

        Exclusion Criteria:

        1) Clinically important pulmonary disease other than asthma. 2) History of anaphylaxis
        following any biologic therapy. 3) Hepatitis B, C or HIV. 4) Pregnant or breastfeeding. 5)
        History of cancer. 6) Current tobacco smoking or a history of tobacco smoking for ≥10
        pack-years. 7) Previous receipt of tralokinumab.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William W Busse, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin School of Medicine and Public Health, Department of Medicine, Allergy &amp; Immunology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Monroeville</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boerne</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brussels (Anderlecht)</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brussels (Woluwé-St-Lambert)</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hasselt</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>GRENOBLE Cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lille Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lyon Cedex 04</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nantes Cedex 1</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>München-Pasing</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bystra Śląska</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lubin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ostrowiec Świętokrzyski</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rzeszów</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wrocław</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dnipropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vinnytsia</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 8, 2017</lastchanged_date>
  <firstreceived_date>October 30, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Reactive Airways</keyword>
  <keyword>Repiratory Tract Disease</keyword>
  <keyword>Obstructive Lung Disease</keyword>
  <keyword>Lung Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
